Fourth-generation allosteric EGFR inhibitors: Structure-based scaffold analysis and SAR exploration.

Abstract

The development of the C797S resistance mutation to third-generation tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer is a key therapeutic barrier, and this renders standard orthosteric site competitive inhibitors futile. Allosteric inhibitors of EGFR have emerged as a promising strategy for overcoming this resistance mechanism due to a structurally distinct binding site approximately 15-20 Å from the C797S mutation that confers potency independent of the status of cysteine-797. This comprehensive review summarizes the last decade of allosteric EGFR inhibitor medicinal chemistry, including 185 compounds across eight scaffold classes representing the entire reported landscape of efforts toward targeting EGFR with small molecules allosterically. The aminothiazole scaffold dominates the field with 57 compounds, followed by 4-anilinoquinazoline with 39 compounds; the focus of the field is concentrated on these privileged scaffolds. Five universal design principles governing allosteric potency have been identified through structure-activity relationship analysis: the formation of a hydrogen bond network, complementarity to a hydrophobic pocket, bivalent binding architecture based on a dual heterocycle, precise linker geometry, and core heterocycle identity. These principles account for the spectacular potency achievements that include 11 compounds reaching ultra-nanomolar potency (IC₅₀ < 1 nM) and 54 compounds attaining single-digit nanomolar activity. The aminothiazole-isoindolinone hybrid attained the most potent compound 4 with 0.10 nM, which is 20-fold, improved from the foundational EAI045 compound. The maturity of the field peaked in 2022 in optimization efforts, with 85 compounds reported. This review establishes that allosteric EGFR inhibition represents a clinically viable strategy for addressing osimertinib resistance, with lead candidates ready for clinical translation.